El colesterol HDL: ¿un nuevo objetivo terapéutico en el manejo de las dislipidemias y la ateroesclerosis? / HDL cholesterol: A new target in the treatment of lipid disorders and atherosclerosis?
Rev. méd. Chile
;
133(7): 823-832, jul. 2005. ilus, tab
Article
Dans Espagnol
| LILACS
| ID: lil-429143
RESUMO
Low plasma HDL cholesterol levels are an independent risk factor for atherosclerotic cardiovascular disease. During the past years, the study of HDL has been stimulated by the discovery of novel genes and proteins, which have provided new insights into the molecular and cellular mechanisms involved in HDL metabolism. In addition, recent clinical studies focused on treating low HDL as primary objective in high cardiovascular risk patients have been very encouraging. Furthermore, new drugs for raising HDL cholesterol are under development. This article reviews the recent progress in the HDL field and its important implications for the pathophysiology and treatment of atherosclerosis. In the near future, we expect that new drugs with specific and beneficial effects on HDL metabolism and the associated cardiovascular risk should improve the current approach to this disease with high burden on health systems and society.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Athérosclérose
/
Dyslipidémies
/
Cholestérol HDL
Type d'étude:
Etude d'étiologie
/
Facteurs de risque
Limites du sujet:
Humains
langue:
Espagnol
Texte intégral:
Rev. méd. Chile
Thème du journal:
Médicament
Année:
2005
Type:
Article
/
descriptif de projet
Pays d'affiliation:
Chili
Institution/Pays d'affiliation:
Clínica Las Condes/CL
/
Pontificia Universidad Católica de Chile/CL
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS